Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 198 institutions reported holding it in 13F filings for Q3 2026, worth $2.01B in total; no superinvestor holds it.
Holders of 5% or more of PVLA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Palvella Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Kaupinen Wes | 13D | 14.60%1.64M shares | New | Dec 20, 20241 filing | Dec 20, 2024 | SEC |
| Jennison Associates LLC | 13G/A | 7.70%1.10M shares | +1.00 ppfrom 6.70% | Aug 3, 20262 filings | Oct 28, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 7.40%822.4K shares | −1.20 ppfrom 8.60% | Dec 20, 20242 filings | Nov 13, 2025 | SEC |
| Prudential Financial Inc | 13G | 6.70%962.4K shares | New | Aug 10, 20261 filing | Aug 10, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.90%848.4K shares | −0.10 ppfrom 6.00% | Jan 8, 20255 filings | Nov 16, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.70%813.0K shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
| First Light Asset Management, LLC | 13G/A | 5.34%769.1K shares | −2.15 ppfrom 7.49% | Feb 17, 20262 filings | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
55 Schedule 13D and 13G filings on Palvella Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 20264:21 PM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 5.90%848.4K shares | −0.10 ppfrom 6.00% | Sep 30, 2026 | SEC |
| Oct 28, 20263:44 PM ET | Jennison Associates LLC | 13G/A | 7.70%1.10M shares | +1.00 ppfrom 6.70% | Sep 30, 2026 | SEC |
| Aug 14, 20264:33 PM ET | First Light Asset Management, LLCand 1 other | 13G/A | 5.34%769.1K shares | −2.15 ppfrom 7.49% | Jun 30, 2026 | SEC |
| Aug 14, 20264:18 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 4.70%672.8K shares | −2.40 ppfrom 7.10%Below 5% | Jun 30, 2026 | SEC |
| Aug 10, 20262:12 PM ET | Prudential Financial Inc | 13G | 6.70%962.4K shares | New | Jun 30, 2026 | SEC |
| Aug 3, 202610:48 AM ET | Jennison Associates LLC | 13G | 6.70%960.6K shares | New | Jun 30, 2026 | SEC |
| Jul 29, 20263:19 PM ET | BlackRock, Inc. | 13G | 5.70%813.0K shares | New | Jun 30, 2026 | SEC |
| Feb 17, 20264:34 PM ET | First Light Asset Management, LLCand 1 other | 13G | 7.49%887.0K shares | New | Dec 31, 2025 | SEC |
| Feb 17, 20264:21 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 7.10%879.0K shares | −2.89 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 13, 20265:33 PM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 6.00%706.4K shares | +1.10 ppfrom 4.90% | Dec 31, 2025 | SEC |
| Nov 14, 20254:19 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.18M shares | – | Sep 30, 2025 | SEC |
| Nov 13, 20255:31 PM ET | Suvretta Capital Management, LLCand 2 others | 13G/A | 7.40%822.4K shares | −1.20 ppfrom 8.60% | Sep 30, 2025 | SEC |
| Aug 14, 20255:26 PM ET | Samsara BioCapital, L.P.and 2 others | 13G/A | 3.10%339.7K shares | −3.00 ppfrom 6.10%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20251:41 PM ET | Frazier Life Sciences Public Fund, L.P.and 19 others | 13G/A | 4.90%545.5K shares | −1.40 ppfrom 6.30%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20259:39 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 6.30%690.0K shares | +1.20 ppfrom 5.10% | Mar 31, 2025 | SEC |
| Jan 8, 20253:04 PM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G | 5.10%575.9K shares | New | Dec 13, 2024 | SEC |
| Dec 20, 20245:32 PM ET | Kaupinen Wesand 4 others | 13D | 14.60%1.64M shares | New | Dec 13, 2024 | SEC |
| Dec 20, 20244:59 PM ET | Samsara BioCapital, L.P.and 2 others | 13G | 6.10%679.5K shares | New | Dec 13, 2024 | SEC |
| Dec 20, 20244:56 PM ET | Suvretta Capital Management, LLCand 2 others | 13G | 8.60%714.5K shares | New | Dec 13, 2024 | SEC |
| Dec 17, 20244:22 PM ET | Dellora Investments LPand 2 others | 13G/A | 1.30%141.1K shares | −9.40 ppfrom 10.70%Below 5% | Dec 13, 2024 | SEC |
| Dec 17, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Dec 6, 20242:21 PM ET | Dellora Investments LPand 2 others | 13G/A | 10.70%141.1K shares | +2.40 ppfrom 8.30% | Nov 6, 2024 | SEC |
| Nov 14, 2024 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Aug 7, 20242:16 PM ET | Dellora Investments LPand 2 others | 13G | 8.30%109.0K shares | New | Jul 24, 2024 | SEC |
| Aug 1, 2024 | ADAR1 Capital Management, LLC | 13GOld format | – | New | – | SEC |
| May 17, 2024 | Biotechnology Value Fund L P | 13GOld format | – | – | – | SEC |
| May 17, 2024 | Biotechnology Value Fund L P | 13GOld format | – | – | – | SEC |
| Feb 14, 2024 | Checkpoint Capital L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Aquilo Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 2, 2024 | Soleus Capital Master Fund, L.P. | 13G/AOld format | – | – | – | SEC |
| Aug 17, 2023 | Biotechnology Value Fund L P | 13D/AOld format | – | – | – | SEC |
| Jun 12, 2023 | Checkpoint Capital L.P. | 13GOld format | – | New | – | SEC |
| May 22, 2023 | Biotechnology Value Fund L P | 13DOld format | – | – | – | SEC |
| Feb 14, 2023 | Aquilo Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Lynx1 Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 20234:20 PM ET | Seagen Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 202310:22 AM ET | AstraZeneca PLC | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2023 | Soleus Capital Master Fund, L.P. | 13GOld format | – | – | – | SEC |
| Jan 26, 2023 | Soleus Capital Master Fund, L.P. | 13G/AOld format | – | – | – | SEC |
| Oct 24, 2022 | Lynx1 Capital Management LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Aquilo Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Nussbaum Ran | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2022 | Soleus Capital Master Fund, L.P. | 13GOld format | – | New | – | SEC |
| Jul 12, 20218:29 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jul 6, 2021 | Citadel Advisors LLC | 13GOld format | – | New | – | SEC |
| Apr 7, 20215:37 PM ET | AstraZeneca PLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
16 notices from officers, directors and other affiliates planning to sell Palvella Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 20264:28 PM ET | Jeffrey MartiniOfficer | 50.0K | $8.70M | Nov 10, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Oct 21, 20264:21 PM ET | Goin KathleenOfficer | 4.31K | $534.5K | Oct 21, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Oct 13, 20264:59 PM ET | Jenkins George MDirector | 27.5K | $3.70M | Oct 13, 202610b5-1 | Piper Sandler & Co | SEC |
| Sep 16, 20264:31 PM ET | Goin KathleenOfficer | 4.30K | $650.5K | Sep 16, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Sep 11, 20264:34 PM ET | Jenkins George MDirector | 27.5K | $4.14M | Sep 11, 202610b5-1 | Piper Sandler | SEC |
| Sep 2, 20264:10 PM ET | Christopher KiritsyDirector | 375 | $58.9K | Sep 2, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 19, 20264:56 PM ET | Goin KathleenOfficer | 4.30K | $647.1K | Aug 19, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Jul 15, 20264:20 PM ET | Goin KathleenOfficer | 4.30K | $643.9K | Jul 15, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Jun 17, 20265:11 PM ET | Goin KathleenOfficer | 4.30K | $476.4K | Jun 17, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| May 20, 20265:47 PM ET | Goin KathleenOfficer | 4.30K | $475.6K | May 20, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Apr 15, 20264:00 PM ET | Goin KathleenOfficer | 4.30K | $557.2K | Apr 15, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Mar 18, 20264:01 PM ET | Goin KathleenOfficer | 4.30K | $519.7K | Mar 18, 202610b5-1 | Piper Sandler and Co | SEC |
| Feb 19, 20265:51 PM ETAmended | Goin KathleenOfficer | 4.30K | $344.5K | Feb 18, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Jan 21, 20264:33 PM ET | Goin KathleenOfficer | 4.30K | $421.6K | Jan 21, 202610b5-1 | Piper Sandler & Co Inc | SEC |
| Dec 17, 20254:33 PM ET | Goin KathleenOfficer | 4.30K | $416.5K | Dec 17, 202510b5-1 | Piper Sandler & Co Inc | SEC |
| Nov 19, 20254:46 PM ET | Goin KathleenOfficer | 4.30K | $356.8K | Nov 19, 202510b5-1 | Piper Sandler & Co Inc | SEC |